Beryl Drugs Profit & Loss Annual

BSE: - | NSE: - | ISIN: - | Sector: -

22.58 -0.46 (-2.00%)Updated : 12 Jun 2026

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	18.38	21.16	25.65	25.76
Other Net	0.49	1.40	0.37	0.27
Diluted Weighted Average Shares	0.51	0.51	0.51	0.51
Depreciation/ Amortization	1.49	1.24	1.19	0.80
Operating Income	0.44	-0.01	1.08	1.13
Net Income	0.42	0.58	0.77	0.77
Income Availableto Com Excl Extra Ord	0.42	0.58	0.77	0.77
Net Income Before Taxes	0.59	0.87	1.01	0.98
Other Operating Expenses Total	4.59	6.92	9.38	8.71
Net Income After Taxes	0.42	0.58	0.77	0.77
Income Availableto Com Incl Extra Ord	0.42	0.58	0.77	0.77
Costof Revenue Total	9.77	10.78	13.15	14.54
Gross Profit	9.05	10.36	13.58	12.35
Interest Inc( Exp) Net- Non- Op Total	-0.34	-0.52	-0.45	-0.42
Diluted Net Income	0.42	0.58	0.77	0.77
Provisionfor Income Taxes	0.16	0.29	0.24	0.22
period Type	-	-	-	-
Net Income Before Extra Items	0.42	0.58	0.77	0.77
Total Revenue	18.82	21.15	26.73	26.89
period Length	12.00	12.00	12.00	12.00
Revenue	18.82	21.15	26.73	26.89
Selling/ General/ Admin Expenses Total	2.53	2.21	1.93	1.70
Diluted Normalized EPS	0.84	1.14	1.50	1.51
Diluted EPS Excluding Extra Ord Items	0.84	1.14	1.52	1.51
Total Adjustmentsto Net Income	-	0.00	-	0.00
Gain( Loss)on Saleof Assets	-	0.00	0.01	-
Interest Exp( Inc) Net- Operating Total	-	0.01	0.01	0.01
Dilution Adjustment	-	-	-	0.00